サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654644

インターベンショナルイメージングの世界市場：2025年～2033年

Global Interventional Imaging Market - 2025-2033

出版日
ページ情報
英文 167 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
インターベンショナルイメージングの世界市場：2025年～2033年
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 167 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

インターベンショナルイメージングの世界市場は、2024年に92億1,000万米ドルに達し、2033年までには166億4,000万米ドルに達すると予測され、予測期間中の2025年から2033年にはCAGR 6.8%で成長すると予測されています。

インターベンショナルイメージングは、低侵襲的な処置や介入を誘導・支援するための高度なイメージング技術の使用を指します。治療中の体内構造を可視化するリアルタイムイメージング技術を含み、ヘルスケア専門家が高精度で正確な処置を行うことを可能にします。インターベンショナルイメージングは、処置中に血管、臓器、組織などの標的部位を連続的にリアルタイムで可視化します。これは、器具を正しく配置し、周辺組織へのダメージを最小限に抑えるために不可欠です。

インターベンショナルイメージング市場は、低侵襲手技への選好の高まり、慢性疾患の有病率の上昇、技術進歩の増加に牽引され、大きな成長を遂げています。例えば、2024年6月、GE HealthCareとMediView XR Inc.は、OmnifyXRインターベンショナル・スイートの最初の設置を発表しました。これは、リアルタイムの医用画像をストリーミングするホログラフィック・ヘッドアップ・ディスプレイと、3次元（3D）解剖学モデルの視覚化および強力な画像処理技術を組み合わせたものです。これにより、幅広いインターベンション技術にわたって精密治療を提供するための遠隔協力が可能になります。

市場力学：

促進要因と抑制要因

技術進歩の高まり

技術的進歩の高まりは、インターベンショナルイメージング市場の成長を大きく後押ししており、低侵襲手技の精度、スピード、安全性を高めることで、予測期間中も市場を牽引していくと予測されます。人工知能は、可視化、画像分析、リアルタイムの意思決定、予測モデリングを改善することで、インターベンショナルイメージングを変革しています。AIアルゴリズムは、画像データから腫瘍や閉塞などの異常を迅速に特定することができ、臨床医がより迅速で正確な判断を下すのに役立ちます。

例えば、2024年12月、Royal Philipsは、最近導入されたCT 5300システムに搭載されたAIとスマートワークフロー自動化機能により、臨床判断支援の信頼性が高まったと発表しました。Philips CT 5300は、革新的なハードウェア、ソフトウェア、人工知能を組み合わせて高品質のスクリーニングを実現し、AI対応のAutomated Philips Advanced Visualization Workspaceアプリケーションによる読影サポートなど、より多くの患者にとって利用しやすいインターベンショナルイメージングを提供します。

さらに、3Dおよび4D画像は、身体構造のリアルタイムで高解像度のビューを提供し、介入中の正確なナビゲーションを支援します。この技術は、血管形成術、生検、腫瘍切除術などの手技のガイドに不可欠です。3Dおよび4Dイメージングの採用は急速に増加し、特に北米や欧州のようなヘルスケアのインフラが整っている地域で市場成長に貢献すると予想されます。

例えば、2024年8月、Siemens Healthineersは、人工知能（AI）特性を備えた新しい心臓血管専用超音波システムACUSON OriginがFDAの認可を取得したと発表しました。これらの特性は、医師が診断、構造的心臓病、電気生理学などの心臓手術をより効果的に実施するのに役立ちます。ACUSON Originのみに対応する新しいAcuNav Lumos 4D ICE（心臓内エコー）カテーテルは、困難な心臓手術のための画像診断の改善を可能にします。

厳しい規制の枠組み

厳しい規制の枠組みは、遅れを生じさせ、コストを増加させ、新技術の採用スピードを制限することにより、インターベンショナルイメージング市場の成長に大きな課題をもたらしています。米国のFDA（食品医薬品局）や欧州のEMA（欧州医薬品庁）などの規制機関は、インターベンショナルイメージングシステムを含む医療機器に厳しい承認プロセスを課しています。これらのプロセスでは、製品が市場に導入される前に、多くの場合、大規模な臨床試験、文書化、審査が行われます。

医療機器の規制基準は地域によって大きく異なります。このような違いは、インターベンショナルイメージング企業にとって世界市場戦略を複雑にしています。各地域で異なる承認プロセスや認証要件（米国ではFDA、欧州ではCEマーキング、オーストラリアではTGAなど）を遵守しなければならないからです。

例えば、FDAで承認された製品が、EUやアジアでは安全性や有効性の基準が異なるため、すぐに販売できない場合があります。そのため、追加の試験や認証が必要となり、市場参入が遅れたり、業務が複雑化したりします。こうした地域ごとの規制の相違は、世界に展開しようとする企業にとって障壁となり、非準拠地域の市場の成長を鈍らせ、最新技術へのアクセスを制限します。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • スニペット：製品タイプ別
  • スニペット：画像モダリティ別
  • スニペット：用途別
  • スニペット：手順タイプ別
  • スニペット：エンドユーザー別
  • スニペット：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 技術の進歩の高まり
    • 抑制要因
      • 厳格な規制枠組み
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名なプレーヤー
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 インターベンショナルイメージング市場、製品タイプ別

  • インターベンショナルイメージングシステム
    • MRIシステム
    • 超音波画像診断システム
    • CTスキャナ
    • 血管造影システム
    • その他
  • インターベンショナルイメージングアクセサリー
    • X線検出器
    • Cアーム
    • 画像増強装置
  • ソフトウェア
  • 消耗品
    • カテーテル
    • ガイドワイヤー
    • 針
    • その他

第6章 インターベンショナルイメージング市場、画像モダリティ別

  • X線画像
  • コンピュータ断層撮影（CT）
  • 磁気共鳴画像（MRI）
  • 超音波画像診断
  • その他

第7章 インターベンショナルイメージング市場、用途別

  • 心臓病学
  • 腫瘍学
  • 神経学
  • 泌尿器科・腎臓科
  • 消化器内科
  • 筋骨格
  • その他

第8章 インターベンショナルイメージング市場、手順タイプ別

  • 診断手順
  • 治療手順

第9章 インターベンショナルイメージング市場、エンドユーザー別

  • 病院
  • 専門クリニック
  • 診断センター
  • 外来手術センター
  • その他

第10章 インターベンショナルイメージング市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢と市場ポジショニング

  • 競合概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第12章 企業プロファイル

  • GE HealthCare
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Koninklijke Philips N.V.
  • Siemens Healthineers AG
  • CANON MEDICAL SYSTEMS USA, INC.
  • FUJIFILM Holdings Corporation
  • Lumibird Medical
  • Boston Scientific Corporation
  • Terumo Corporation
  • Guerbet
  • Shimadzu Corporation

第13章 前提条件と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第14章 付録

目次
Product Code: MI9090

The global interventional imaging market reached US$ 9.21 billion in 2024 and is expected to reach US$ 16.64 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033.

Interventional imaging refers to the use of advanced imaging techniques to guide and assist minimally invasive procedures or interventions. It involves real-time imaging technology to visualize internal structures of the body during medical treatments, enabling healthcare professionals to perform procedures with high precision and accuracy. Interventional imaging provides continuous, real-time visualization of the target area, such as blood vessels, organs, or tissues, during a procedure. This is essential for ensuring the correct placement of instruments and minimizing damage to surrounding tissues.

The interventional imaging market is experiencing significant growth, driven by a rising preference for minimally invasive procedures, a rising prevalence of chronic diseases and increasing technological advancements. For instance, in June 2024, GE HealthCare and MediView XR Inc. released the first installation of the OmnifyXR interventional suite. It combines a holographic heads-up display that streams real-time medical images with three-dimensional (3D) anatomical model visualization and powerful imaging technology. It enables remote cooperation for the delivery of precision care across a wide range of intervention techniques.

Market Dynamics: Drivers & Restraints

Rising technological advancements

The rising technological advancements are significantly driving the growth of the interventional imaging market and are expected to drive the market over the forecast period by enhancing the accuracy, speed, and safety of minimally invasive procedures. Artificial intelligence is transforming interventional imaging by improving visualization, image analysis, real-time decision-making, and predictive modeling. AI algorithms can quickly identify abnormalities, such as tumors or blockages, from imaging data, helping clinicians make faster, more accurate decisions.

For instance, in December 2024, Royal Philips announced a boost in confidence in clinical decision support with AI and smart workflow automation capabilities in the recently introduced CT 5300 system. Philips CT 5300 combines innovative hardware, software and artificial intelligence for high-quality screening, and interventional imaging accessible to more patients, including reading support with Automated AI-enabled Philips Advanced Visualization Workspace applications.

Additionally, 3D and 4D imaging provide real-time, high-resolution views of the body's structures, aiding in precise navigation during interventions. This technology is crucial for guiding procedures like angioplasty, biopsy, and tumor ablation. The adoption of 3D and 4D imaging is expected to increase rapidly, contributing to market growth, especially in regions with high healthcare infrastructure, like North America and Europe.

For instance, in August 2024, Siemens Healthineers announced that ACUSON Origin, a new specialized cardiovascular ultrasound system with artificial intelligence (AI) characteristics, has received FDA clearance. These qualities can help physicians execute cardiac operations more effectively, such as diagnostics, structural heart disease, and electrophysiology. The new AcuNav Lumos 4D ICE (intracardiac echocardiography) catheter, which is only compatible with the ACUSON Origin, enables improved imaging for difficult heart surgeries.

Strict regulatory frameworks

Strict regulatory frameworks pose a significant challenge to the growth of the interventional imaging market by creating delays, adding costs and restricting the speed at which new technologies can be adopted. Regulatory bodies, such as the FDA (Food and Drug Administration) in the U.S. and the European Medicines Agency (EMA) in Europe, impose stringent approval processes for medical devices, including interventional imaging systems. These processes often involve extensive clinical trials, documentation, and reviews before products can be introduced to the market.

Regulatory standards for medical devices vary significantly across regions. These differences complicate the global market strategy for interventional imaging companies, as they must adhere to different approval processes and certification requirements in each region (e.g., FDA in the U.S., CE marking in Europe, and TGA in Australia).

For instance, a product approved by the FDA might not be immediately eligible for sale in the EU or Asia due to differences in safety and efficacy standards. This requires additional testing and certifications, which can delay market entry and increase operational complexity. These regional regulatory discrepancies create barriers for companies trying to expand globally and slow down the growth of the market in non-compliant regions, limiting access to the latest technologies.

Segment Analysis

The global interventional imaging market is segmented based on product type, imaging modality, application, procedure type, end-user and region.

Product Type:

The interventional imaging systems segment is expected to dominate the interventional imaging market share

Interventional imaging systems such as MRI systems, ultrasound imaging systems and angiography systems provide real-time, detailed visual guidance during minimally invasive procedures, such as angioplasty, biopsy and tumor ablation. These systems are integral to ensuring precise targeting, reducing complications, and improving patient outcomes.

For instance, in cardiology, systems like GE Healthcare's fluoroscopy systems are widely used to guide procedures such as coronary angioplasty and stent placement, ensuring correct catheter positioning in real time. The demand for such procedures, which benefit from precise guidance, is increasing, positioning interventional imaging systems as the market leader.

Advanced imaging technologies, such as 3D/4D imaging, robotic-assisted systems and AI-powered diagnostic tools, are transforming interventional imaging systems, enhancing their accuracy, efficiency, and applicability. For instance, the Siemens Healthineers' ARTIS pheno system integrates 3D imaging with cutting-edge advanced robotic-assisted interventions, for multiple surgical and interventional procedures. The continuous innovation in imaging systems, such as the integration of AI for faster and more accurate imaging analysis, ensures their dominance in the interventional imaging market.

Geographical Analysis

North America is expected to hold a significant position in the interventional imaging market share

North America, particularly the United States, is home to major medical imaging companies such as GE Healthcare, Philips, and Siemens Healthineers. These companies are at the forefront of developing and commercializing new imaging technologies, including 3D/4D imaging, robotic-assisted interventions, and AI-powered imaging systems.

For instance, in November 2024, Philips Healthcare launched a limited release of the LumiGuide system, a new light-based catheter guidance system for cath labs that represents a step toward radiation-free interventional imaging. The focus of the technology is endovascular aortic procedures. LumiGuide system works exclusively with compatible Philips interventional systems such as Azurion and is the second-generation solution to use FORS. These continuous technological advancements and innovations in the region solidify North America's position as a leader in the interventional imaging market.

There is a rising preference for minimally invasive procedures in North America due to the benefits of shorter recovery times, reduced risks, and lower healthcare costs. Interventional imaging systems are essential in guiding these procedures with precision, which further drives their demand. For instance, the growing use of angioplasty and stent placement procedures for coronary artery disease (CAD) is driving the demand for advanced fluoroscopy and angiography systems in the U.S. The increasing demand for minimally invasive procedures is fueling the growth of the interventional imaging market in North America, as these systems are crucial for performing such interventions with high accuracy.

Asia-Pacific is growing at the fastest pace in the interventional imaging market

Asia-Pacific is seeing an influx of technological advancements in interventional imaging, with an increasing number of local manufacturers producing cost-effective, high-quality imaging systems. This trend is driving adoption by making interventional imaging more accessible in emerging markets. The presence of leading manufacturers such as India's Medtronic and Philips India and more affordable imaging systems are driving the growth of the interventional imaging market in the region, making advanced technologies more accessible to a broader population.

For instance, in November 2024, Philips India launched the new Azurion to expert interventionalists in cardiology, neurology, vascular medicine, and surgery in India. The new interventional system is intended to speed up neurovascular operations and assist care teams in making the correct decisions faster, treating more patients, and achieving better results. It has increased C-arm rotation and angulation. It also includes parking facilities for quick transitions from 2D to 3D imaging, comprehensive table-side control that eliminates the need to leave the sterile field, automatic beam rotation to obtain correctly oriented images for all angulations and rotations, and a new head immobilizer to support improved stroke care.

Competitive Landscape

The major global players in the interventional imaging market include GE HealthCare, Koninklijke Philips N.V., Siemens Healthineers AG, CANON MEDICAL SYSTEMS USA, INC., FUJIFILM Holdings Corporation, Lumibird Medical, Boston Scientific Corporation, Terumo Corporation, Guerbet, Shimadzu Corporation and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global interventional imaging market report delivers a detailed analysis with 78 key tables, more than 80 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Imaging Modality
  • 2.5. Snippet by Application
  • 2.6. Snippet by Procedure Type
  • 2.7. Snippet by End-User
  • 2.8. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Strict Regulatory Frameworks
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Interventional Imaging Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Interventional Imaging Systems*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. MRI Systems
    • 5.2.4. Ultrasound Imaging Systems
    • 5.2.5. CT Scanners
    • 5.2.6. Angiography Systems
    • 5.2.7. Others
  • 5.3. Interventional Imaging Accessories
    • 5.3.1. X-ray Detectors
    • 5.3.2. C-arms
    • 5.3.3. Image Intensifiers
  • 5.4. Software
  • 5.5. Consumables
    • 5.5.1. Catheters
    • 5.5.2. Guidewires
    • 5.5.3. Needles
    • 5.5.4. Others

6. Interventional Imaging Market, By Imaging Modality

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 6.1.2. Market Attractiveness Index, By Imaging Modality
  • 6.2. X-Ray Imaging*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Computed Tomography (CT)
  • 6.4. Magnetic Resonance Imaging (MRI)
  • 6.5. Ultrasound Imaging
  • 6.6. Others

7. Interventional Imaging Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Cardiology*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Oncology
  • 7.4. Neurology
  • 7.5. Urology and Nephrology
  • 7.6. Gastroenterology
  • 7.7. Musculoskeletal
  • 7.8. Others

8. Interventional Imaging Market, By Procedure Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 8.1.2. Market Attractiveness Index, By Procedure Type
  • 8.2. Diagnostic Procedure*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Therapeutic Procedure

9. Interventional Imaging Market, By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Diagnostic Centers
  • 9.5. Ambulatory Surgical Centers
  • 9.6. Others

10. Interventional Imaging Market, By Regional Market Analysis and Growth Opportunities

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.8.1. U.S.
      • 10.2.8.2. Canada
      • 10.2.8.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.8.1. Germany
      • 10.3.8.2. U.K.
      • 10.3.8.3. France
      • 10.3.8.4. Spain
      • 10.3.8.5. Italy
      • 10.3.8.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.8.1. Brazil
      • 10.4.8.2. Argentina
      • 10.4.8.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.8.1. China
      • 10.5.8.2. India
      • 10.5.8.3. Japan
      • 10.5.8.4. South Korea
      • 10.5.8.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape and Market Positioning

  • 11.1. Competitive Overview and Key Market Players
  • 11.2. Market Share Analysis and Positioning Matrix
  • 11.3. Strategic Partnerships, Mergers & Acquisitions
  • 11.4. Key Developments in Product Portfolios and Innovations
  • 11.5. Company Benchmarking

12. Company Profiles

  • 12.1. GE HealthCare*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
    • 12.1.5. SWOT Analysis
  • 12.2. Koninklijke Philips N.V.
  • 12.3. Siemens Healthineers AG
  • 12.4. CANON MEDICAL SYSTEMS USA, INC.
  • 12.5. FUJIFILM Holdings Corporation
  • 12.6. Lumibird Medical
  • 12.7. Boston Scientific Corporation
  • 12.8. Terumo Corporation
  • 12.9. Guerbet
  • 12.10. Shimadzu Corporation

LIST NOT EXHAUSTIVE

13. Assumption and Research Methodology

  • 13.1. Data Collection Methods
  • 13.2. Data Triangulation
  • 13.3. Forecasting Techniques
  • 13.4. Data Verification and Validation

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us